BeOne Medicines (ONC)
NASDAQ:ONC
Want to see ONC full AI Analyst Report?
ONC Stock Chart & Stats
$323.87
--
Market closed
$323.87
--
Day’s Range― - ―
52-Week Range$218.31 - $385.22
Previous CloseN/A
VolumeN/A
Average Volume (3M)206.71K
Market Cap
$33.58B
Enterprise Value$33.37B
Total Cash (Recent Filing)$4.55B
Total Debt (Recent Filing)$2.00B
Price to Earnings (P/E)124.6
Beta0.76
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)23.24
Shares Outstanding109,720,300
10 Day Avg. Volume214,251
30 Day Avg. Volume206,705
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)7.60
Price to Sales (P/S)6.20
P/FCF Ratio35.18
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue6.24
Enterprise Value/Gross Profit7.14
Enterprise Value/Ebitda44.60
Forecast
1Y Price Target
$388.54Price Target Upside19.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)6.13
Revenue Forecast (FY)$6.40B
Bulls Say, Bears Say
Bulls Say
Pipeline And Regulatory CatalystsAnalyst cites several clinical and regulatory catalysts, including potential approvals, late-stage trial readouts, a planned Phase 3 breast cancer trial, and a BTK degrader advancing toward registration, that could drive material upside.
Product LeadershipAnalyst highlights Brukinsa's position as a category-leading flagship and notes Zanubrutinib's rapid market-share gains, supporting continued prescription momentum for the oncology franchise.
Profitability And Balance SheetAnalyst notes strong sales momentum combined with disciplined cost control and a strengthened cash position after a royalty sale as drivers of sustained profitability.
Bears Say
Competition Risk From Fixed-duration TherapiesAnalyst notes guidance assumes only modest competition from rival fixed-duration regimens, which could introduce downside if those therapies gain broader adoption than expected.
Competition Risk From New BTK InhibitorsAnalyst warns guidance assumes limited impact from emerging non-covalent BTK inhibitors, creating potential downside if these rivals erode market share faster than anticipated.
Revenue Guidance MissAnalyst observes management's revenue guidance came modestly below prior expectations, creating downward pressure on analyst forecasts and valuation assumptions.
BeOne Medicines News
ONC FAQ
What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was $218.31 and its highest was $385.22 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $33.58B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s upcoming earnings report date is Aug 21, 2026 which is in 106 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on May 06, 2026. The company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.439 by $0.521.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,720,300 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of $1.96 in its last earnings report, beating expectations of $1.439. Following the earnings report the stock price went down -8.477%.
Which hedge fund is a major shareholder of BeOne Medicines?
Currently, no hedge funds are holding shares in ONC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$388.54 (19.97% Upside)
$388.54 (19.97% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 17.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.21%
12-Months-Change
Fundamentals
Return on Equity
7.31%
Trailing 12-Months
Asset Growth
38.94%
Trailing 12-Months
Company Description
BeOne Medicines
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
ONC Company Deck
ONC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive commercial and R&D narrative: robust revenue and margin expansion, GAAP profitability, substantial free cash flow, BRUKINSA’s clear commercial leadership backed by best‑in‑class long‑term data, multiple regulatory wins and rapid pipeline advancement. Notable risks discussed include safety/efficacy concerns with some fixed‑duration competitor regimens, competitive dynamics that require longer follow‑up, one‑time accounting/tax items and elevated operating investment for 2026. On balance the financial strength, clinical momentum and strategic pipeline depth outweigh the operational and competitive uncertainties noted.View all ONC earnings summariesONC Stock 12 Month Forecast
Average Price Target
$388.54
▲(19.97% Upside)
Technical Analysis
Ownership Overview
68.05% Insiders
11.97% Mutual Funds
0.31% Other Institutional Investors
18.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---